Abstract 1279
Background
The newly created Department of Oncology Nurse Coordinators, in this case the Digestive Oncology department, ONCDOD, at the Jules Bordet Institute, allows patients, mainly the newly diagnosed, to early personalized medicine. The aim is to orient the patients to all the services available and implicated to his/her care; to explain the treatment, procedures for therapies and answer questions; to be present for the patient and his family so as to create a climate of confidence, comfort and security.
Methods
60 newly diagnosed digestive patients were followed by the Nurse Coordinator in the year 2018. The necessary care requirements for this group of patients were identified, recorded and analysed in collaboration with the multidisciplinary team. With the help of an exhaustive data on the patient, all the Oncology Nurse Coordinator’s activities were reported in a unique, accessible electronic patient’s file.
Results
Thanks to knowledge of the patient’s medical situation, but also to his psychological and socioeconomic environment, the interventions of the Oncology Nurse Coordinator allowed a more fluid path of diagnosis and treatment, rapid and efficient care of treatment side effects, avoid unnecessary hospitalization and ensure more comfort and security for the patient.
Conclusions
The daily follow-up of newly diagnosed digestive patients, allowed a more effective taking care of patients from the diagnosis. The patients showed confidence and serenity knowing that they can call one single person, anytime, in the hospital for all their questions and needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fouad Awada.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract